Daniel S. Mytelka

Daniel S. Mytelka

Auto-generated profile, based on publicly available information

Daniel S. Mytelka

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2010 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
SPSteven M. Paul
Steven M. Paul
DMDaniel S. Mytelka
Daniel S. Mytelka
CDChristopher T. Dunwiddie
Christopher T. Dunwiddie
CPCharles C. Persinger
Charles C. Persinger
BMBernard H. Munos
Bernard H. Munos
ASAaron L. Schacht
Aaron L. Schacht

1 January 1996 in Journal of Bacteriology
Verified
Journal Article
Closed access
PDF file
DMD S Mytelka
D S Mytelka
MCM J Chamberlin
M J Chamberlin
We have cloned the Escherichia coli fliAZY operon, which contains the fliA gene (the alternative sigma factor sigma F) and two novel genes, fliZ and fliY. Transcriptional mapping of this operon shows two start sites, one of which is preceded by a canonical E sigma F-dependent consensus and is dependent on sigma F for expression in vivo and in vitro. We have overexpressed and purified sigma F and demonstrated that it can direct core polymerase to E sigma F-dependent promoters. FliZ and FliY are not required for motility but may regulate sigma F activity, perhaps in response to a putative cell density signal that may be detected by FliY, a member of the bacterial extracellular solute-binding protein family 3.

20 March 2015 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
LHLisa M Hess
Lisa M Hess
DMDiane Michael
Diane Michael
DMDaniel S. Mytelka
Daniel S. Mytelka
JBJulie Beyrer
Julie Beyrer
ALAstra M. Liepa
Astra M. Liepa
SNSteven Nicol
Steven Nicol
The aim of this study was to conduct a retrospective database analysis to describe the chemotherapy treatment patterns and outcomes of patients with gastric cancer.

4 December 2017 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
DMDaniel S. Mytelka
Daniel S. Mytelka
LLLi Li
Li Li
KBKarin Benoit
Karin Benoit
Background: Cachexia and its most visible manifestation, weight loss, represent important poor prognostic factors for patients with non‐small cell lung cancer. This work examines how severity of weight loss as an indicator of cachexia affects outcomes.Methods: In a retrospective observational study of electronic medical records, patients with non‐small cell lung cancer were monitored for weight loss from an initial assessment (within 2 months of index diagnosis) to a landmark at 5 months (at least 3 months after initial assessment). Patients who survived to the landmark were then followed to determine the association of baseline body mass index (BMI) and weight loss during the assessment period with outcomes. Patients were clustered to determine how BMI and weight loss related to survival as approximated by time of last appearance in the database, a strong proxy for time of death.Results: Twelve thousand one hundred and one patients were divided into 5 cachexia risk groups based on a combination of weight loss and initial BMI. More severe groups demonstrated progressively worse outcomes, with the most severe group surviving for a median of 263 days (95% CI 254–274) from index and having a 1‐year survival rate of 31%. The least severe group survived for a median of 825 days from index (95% CI 768–908) and had a 1‐year survival rate of 78%. Cachexia risk group was a stronger predictor of survival than any baseline variable, including disease stage, performance status, or age.Conclusions: In this study, we showed that increasing weight loss and, to a lesser extent, decreasing BMI, led to substantially worse outcomes for non‐small cell lung cancer patients independent of other variables. We suggest risk score groups that provide an improved approach for identifying poor prognosis patients with the greatest need.

1 July 1996 in Nucleic Acids Research
Verified
Journal Article
Closed access
DMD. S. Mytelka
D. S. Mytelka
MCM. J. Chamberlin
M. J. Chamberlin
We have studied a novel class of DNA sequences that cause DNA polymerases to pause. These sequences have the central consensus Py-G-C and are not necessarily adjacent to hairpins in the DNA template. Since most consensus sequences do not cause pauses under standard conditions, additional template features must exist that make it difficult to incorporate nucleotides at these positions. We believe that these pauses result from constraints that make the conformation change involved in nucleotide selection more difficult. These pauses can obscure parts of DNA sequencing ladders and prevent DNA amplification by the polymerase chain reaction. The addition of betaine, and some related compounds, relieves these pauses.

24 May 2018 in Sarcoma
Verified
Journal Article
Open access
PDF file
SNSaurabh P. Nagar
Saurabh P. Nagar
DMDaniel S. Mytelka
Daniel S. Mytelka
SCSean D. Candrilli
Sean D. Candrilli
YDYulia D’yAchkova
Yulia D’yAchkova
MLMaria Lorenzo
Maria Lorenzo
JKJames A. Kaye
James A. Kaye
Objective. To describe real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy in the United Kingdom, Spain, Germany, and France. Methods. Physicians completed a web-based medical record abstraction for adult patients with advanced STS (other than Kaposi’s sarcoma or gastrointestinal stromal tumor) who received ≥1 line of systemic therapy. Clinical characteristics, treatments, tumor responses, and mortality data were recorded. Results. A total of 130 physicians provided data for 807 patients. Patients’ mean age at advanced STS diagnosis was 57.1 (±12.3) years; 59% were male. The most commonly identified histologic categories were leiomyosarcoma (28%), liposarcoma (13%), and rhabdomyosarcoma (11%). Overall, 57% of patients received only 1 line of therapy, 32% received 2 lines of therapy, and 11% received ≥3 lines of therapy. The most common first-line regimens were doxorubicin alone (41%), doxorubicin plus ifosfamide (19%), docetaxel plus gemcitabine (9%), paclitaxel alone (4%), and ifosfamide (4%). Median overall survival from start of treatment was estimated to be 17.6 months (95% confidence interval, 15.6–19.0 months). Conclusions. In real-world clinical practice, advanced STS is most commonly treated with older therapies in the United Kingdom, Spain, Germany, and France. New therapies that improve overall survival in advanced STS are needed.